课题基金 / 基金详情

Comparative effectiveness of strategies to improve iron chelation in thalassemia

Comparative effectiveness of strategies to improve iron chelation in thalassemia
改善地中海贫血铁螯合策略的有效性比较
批准号:
8144713
负责人:
Janet L Kwiatkowski
金额:
$43.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-15 至 2013-06-30

项目摘要

项目成果

Janet L Kwiatkowski的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该提案是一项针对未来比较有效性研究(CER)项目的多中心计划拨款,旨在改善输血依赖性地中海贫血患者的铁负担。在世界范围内,(非移植)地中海贫血重症患者的护理标准是持续输血治疗加终身铁螯合治疗。在过去的三十年中,这种疗法改善了地中海贫血患者的寿命,但螯合是否充足是可变的,死亡的主要原因仍然是心脏铁超载。MRI铁测量简化了对全身和心脏铁负荷的评估,但许多患者的螯合状态并不理想。许多因素影响螯合的充分性,包括输血负担和依从性。选择螯合剂和给药方案也是至关重要的因素,但“最佳”策略目前尚不清楚。由于许多原因,这种知识的缺乏不适合随机临床试验,例如(a)当口服螯合剂可用时,患者不愿意随机接受肠外治疗,(b)不同国家螯合剂的监管批准状态不同,以及(c)支持在螯合剂品牌之间和/或在螯合剂品牌之间随机联合治疗方法的后勤、财务和企业障碍。该提案的工作假设是地中海贫血纵向队列(TLC),一个正在进行的nhlbi资助的项目,捕获螯合剂方案,铁状态,输血负担,依从性和终末器官功能的测量,约400名患者,可以形成一项观察性研究的框架,该研究将成为计划在美国,加拿大,英国TLC站点和泰国新计划站点进行的CER研究的基础。该项目将在两个具体目标中完成:目标1是为地中海贫血专业的铁螯合的多中心国际CER研究开发框架和基础设施。目的2是为计划中的R01应用提供螯合剂策略的可行性信息和探索性分析。aim 2中初始分析的反馈将被迭代地用于改善aim 1的物流,以预期2012年的R01应用。
英文摘要
DESCRIPTION (provided by applicant): This proposal is a multicenter planning grant toward a future comparative effectiveness research (CER) project aimed at improving the iron burden of transfusion-dependent thalassemia patients. Worldwide, the standard of care for (non-transplanted) thalassemia major patients is ongoing transfusion therapy plus lifelong iron chelation. This therapy has improved lifespan in thalassemia over the last three decades, but chelation adequacy is variable, and the leading cause of death remains cardiac iron overload. Iron measurements by MRI have simplified assessment of total-body and cardiac iron burden, yet chelation status of many patients is suboptimal. Many factors affect adequacy of chelation, including transfusion burden and adherence. Choice of chelator(s) and dose regimen(s) are also vital factors, but the "optimal" strategy is unclear presently. This lack of knowledge is not amenable to randomized clinical trials for many reasons, e.g. (a) unwillingness of patients to be randomized to parenteral therapy when oral chelators are available, (b) varying regulatory approval status of the chelators in different countries, and (c) logistical, financial and corporate impediments for supporting randomized combination therapy approaches between and/or among chelator brands. The working hypothesis for this proposal is that the Thalassemia Longitudinal Cohort (TLC), an ongoing NHLBI-funded project which captures chelator regimens, iron status, transfusion burden, and measures of adherence and end-organ function for ~400 patients, can form the framework of an observational study that will underlie the planned CER study at TLC sites in the US, Canada, the UK and a new planned site in Thailand. The project will be accomplished in two specific aims: Aim 1 is to develop the framework and infrastructure for a multicenter, international CER study of iron chelation in thalassemia major. Aim 2 is to provide both feasibility information and exploratory analyses of chelator strategies for the planned R01 application. Feedback from initial analyses in aim 2 will be used iteratively to improve Aim 1 logistics in anticipation of an R01 application in 2012. PUBLIC HEALTH RELEVANCE The project aims to determine the most effective strategies for iron chelation in chronically transfused thalassemia major patients. Although chelators have greatly improved life- expectancy in thalassemia over the last three decades, many patients have unsatisfactory cardiac and whole-body iron burdens, and cardiac siderosis remains the leading cause of death in young adults with thalassemia in developed countries. The problem is refractory to approaches by randomized clinical trials not only for logistical and financial reasons, but also the impossibility of using parenteral deferoxamine as a randomized comparator arm, now that oral chelators are available worldwide. We therefore propose a Comparative Effectiveness Research approach, which will be based on the ongoing Thalassemia Longitudinal Cohort study, with addition of a large international site to the current multi-site, multinational observational cohort. The R34 project will establish the infrastructure for a full CER trial, and provide pilot data on feasibility and the analysis methods themselves. Thalassemia remains one of the most prevalent genetic conditions worldwide, and the results of this project will lead directly to improved global research collaboration and improved individualized therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Eleventh Cooley's Anemia Symposium
  • 批准号:
    10538276
  • 项目类别:
  • 资助金额:
    $1.0万
  • 财政年份:
    2022
  • 负责人:
    Janet L Kwiatkowski
  • 依托单位:
Comparative effectiveness of strategies to improve iron chelation in thalassemia
  • 批准号:
    8313893
  • 项目类别:
  • 资助金额:
    $39.28万
  • 财政年份:
    2011
  • 负责人:
    Janet L Kwiatkowski
  • 依托单位:
Thalassemia Clinical Research Network
  • 批准号:
    7097463
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2000
  • 负责人:
    Janet L Kwiatkowski
  • 依托单位:
Thalassemia Clinical Research Network
  • 批准号:
    7475887
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2000
  • 负责人:
    Janet L Kwiatkowski
  • 依托单位:
海外基金